Department of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden.
Department of Pediatrics, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Cochrane Database Syst Rev. 2023 Apr 5;4(4):CD015056. doi: 10.1002/14651858.CD015056.pub2.
Neonates might be exposed to numerous painful procedures due to diagnostic reasons, therapeutic interventions, or surgical procedures. Options for pain management include opioids, non-pharmacological interventions, and other drugs. Morphine, fentanyl, and remifentanil are the opioids most often used in neonates. However, negative impact of opioids on the structure and function of the developing brain has been reported.
To evaluate the benefits and harms of opioids in term or preterm neonates exposed to procedural pain, compared to placebo or no drug, non-pharmacological intervention, other analgesics or sedatives, other opioids, or the same opioid administered by a different route.
We used standard, extensive Cochrane search methods. The latest search date was December 2021.
We included randomized controlled trials conducted in preterm and term infants of a postmenstrual age (PMA) up to 46 weeks and 0 days exposed to procedural pain where opioids were compared to 1) placebo or no drug; 2) non-pharmacological intervention; 3) other analgesics or sedatives; 4) other opioids; or 5) the same opioid administered by a different route.
We used standard Cochrane methods. Our primary outcomes were pain assessed with validated methods and any harms. We used a fixed-effect model with risk ratio (RR) for dichotomous data and mean difference (MD) for continuous data, and their confidence intervals (CI). We used GRADE to assess the certainty of the evidence for each outcome.
We included 13 independent studies (enrolling 823 newborn infants): seven studies compared opioids to no treatment or placebo (the main comparison in this review), two studies to oral sweet solution or non-pharmacological intervention, and five studies (of which two were part of the same study) to other analgesics and sedatives. All studies were performed in a hospital setting. Opioids compared to placebo or no drug Compared to placebo, opioids probably reduce pain score assessed with the Premature Infant Pain Profile (PIPP)/PIPP-Revised (PIPP-R) scale during the procedure (MD -2.58, 95% CI -3.12 to -2.03; 199 participants, 3 studies; moderate-certainty evidence); may reduce Neonatal Infant Pain Scale (NIPS) during the procedure (MD -1.97, 95% CI -2.46 to -1.48; 102 participants, 2 studies; low-certainty evidence); and may result in little to no difference in pain score assessed with the Douleur Aiguë du Nouveau-né (DAN) scale one to two hours after the procedure (MD -0.20, 95% CI -2.21 to 1.81; 42 participants, 1 study; low-certainty evidence). The evidence is very uncertain about the effect of opioids on pain score assessed with the PIPP/PIPP-R scale up to 30 minutes after the procedure (MD 0.14, 95% CI -0.17 to 0.45; 123 participants, 2 studies; very low-certainty evidence) or one to two hours after the procedure (MD -0.83, 95% CI -2.42 to 0.75; 54 participants, 2 studies; very low-certainty evidence). No studies reported any harms. The evidence is very uncertain about the effect of opioids on episodes of bradycardia (RR 3.19, 95% CI 0.14 to 72.69; 172 participants, 3 studies; very low-certainty evidence). Opioids may result in an increase in episodes of apnea compared to placebo (RR 3.15, 95% CI 1.08 to 9.16; 199 participants, 3 studies; low-certainty evidence). The evidence is very uncertain about the effect of opioids on episodes of hypotension (RR not estimable, risk difference 0.00, 95% CI -0.06 to 0.06; 88 participants, 2 studies; very low-certainty evidence). No studies reported parent satisfaction with care provided in the neonatal intensive care unit (NICU). Opioids compared to non-pharmacological intervention The evidence is very uncertain about the effect of opioids on pain score assessed with the Crying Requires oxygen Increased vital signs Expression Sleep (CRIES) scale during the procedure when compared to facilitated tucking (MD -4.62, 95% CI -6.38 to -2.86; 100 participants, 1 study; very low-certainty evidence) or sensorial stimulation (MD 0.32, 95% CI -1.13 to 1.77; 100 participants, 1 study; very low-certainty evidence). The other main outcomes were not reported. Opioids compared to other analgesics or sedatives The evidence is very uncertain about the effect of opioids on pain score assessed with the PIPP/PIPP-R during the procedure (MD -0.29, 95% CI -1.58 to 1.01; 124 participants, 2 studies; very low-certainty evidence); up to 30 minutes after the procedure (MD -1.10, 95% CI -2.82 to 0.62; 12 participants, 1 study; very low-certainty evidence); and one to two hours after the procedure (MD -0.17, 95% CI -2.22 to 1.88; 12 participants, 1 study; very low-certainty evidence). No studies reported any harms. The evidence is very uncertain about the effect of opioids on episodes of apnea during (RR 3.27, 95% CI 0.85 to 12.58; 124 participants, 2 studies; very low-certainty evidence) and after the procedure (RR 2.71, 95% CI 0.11 to 64.96; 124 participants, 2 studies; very low-certainty evidence) and on hypotension (RR 1.34, 95% CI 0.32 to 5.59; 204 participants, 3 studies; very low-certainty evidence). The other main outcomes were not reported. We identified no studies comparing different opioids (e.g. morphine versus fentanyl) or different routes for administration of the same opioid (e.g. morphine enterally versus morphine intravenously).
AUTHORS' CONCLUSIONS: Compared to placebo, opioids probably reduce pain score assessed with PIPP/PIPP-R scale during the procedure; may reduce NIPS during the procedure; and may result in little to no difference in DAN one to two hours after the procedure. The evidence is very uncertain about the effect of opioids on pain assessed with other pain scores or at different time points. No studies reported if any harms occurred. The evidence is very uncertain about the effect of opioids on episodes of bradycardia or hypotension. Opioids may result in an increase in episodes of apnea. No studies reported parent satisfaction with care provided in the NICU. The evidence is very uncertain about the effect of opioids on any outcome when compared to non-pharmacological interventions or to other analgesics. We identified no studies comparing opioids to other opioids or comparing different routes of administration of the same opioid.
由于诊断、治疗干预或手术的原因,新生儿可能会经历许多疼痛程序。疼痛管理的选择包括阿片类药物、非药物干预和其他药物。吗啡、芬太尼和瑞芬太尼是新生儿最常使用的阿片类药物。然而,已经有报道称阿片类药物对发育中大脑的结构和功能有负面影响。
评估在经历程序性疼痛的足月或早产儿中,与安慰剂或无药物、非药物干预、其他镇痛剂或镇静剂、其他阿片类药物或相同阿片类药物的不同给药途径相比,阿片类药物的益处和危害。
我们使用了标准的、广泛的 Cochrane 检索方法。最新检索日期为 2021 年 12 月。
我们纳入了在妊娠龄(PMA)达 46 周和 0 天之前接受程序性疼痛的早产儿和足月儿的随机对照试验,其中阿片类药物与 1)安慰剂或无药物;2)非药物干预;3)其他镇痛剂或镇静剂;4)其他阿片类药物;或 5)相同阿片类药物的不同给药途径进行比较。
我们使用了标准的 Cochrane 方法。我们的主要结局是使用经过验证的方法评估疼痛和任何危害。我们使用固定效应模型,对于二分类数据使用风险比(RR),对于连续数据使用均数差(MD)及其置信区间(CI)。我们使用 GRADE 评估每个结局的证据确定性。
我们纳入了 13 项独立的研究(共纳入 823 名新生儿):7 项研究将阿片类药物与安慰剂或无治疗进行比较(本综述的主要比较),2 项研究与口服甜味溶液或非药物干预进行比较,5 项研究(其中 2 项为同一研究的一部分)与其他镇痛剂和镇静剂进行比较。所有研究均在医院环境中进行。
与安慰剂或无药物相比,阿片类药物可能会减轻程序性疼痛评分(采用 Premature Infant Pain Profile 量表[PIPP]或 PIPP 修订版[PIPP-R]评估)(MD-2.58,95%CI-3.12 至-2.03;199 名参与者,3 项研究;中等确定性证据);可能会减轻新生儿疼痛量表(NIPS)在程序中的评分(MD-1.97,95%CI-2.46 至-1.48;102 名参与者,2 项研究;低确定性证据);可能导致在程序后 1 至 2 小时的 DAN 评分(MD-0.20,95%CI-2.21 至 1.81;42 名参与者,1 项研究;低确定性证据)差异无统计学意义。关于阿片类药物对程序后 30 分钟内(MD 0.14,95%CI-0.17 至 0.45;123 名参与者,2 项研究;非常低确定性证据)或 1 至 2 小时后(MD-0.83,95%CI-2.42 至 0.75;54 名参与者,2 项研究;非常低确定性证据)的 PIPP/PIPP-R 评分的影响,证据非常不确定。没有研究报告任何危害。关于阿片类药物对心动过缓发作(RR 3.19,95%CI 0.14 至 72.69;172 名参与者,3 项研究;非常低确定性证据)的影响,证据非常不确定。阿片类药物可能导致与安慰剂相比,呼吸暂停发作增加(RR 3.15,95%CI 1.08 至 9.16;199 名参与者,3 项研究;低确定性证据)。关于阿片类药物对低血压发作(RR 不可估计,风险差异 0.00,95%CI-0.06 至 0.06;88 名参与者,2 项研究;非常低确定性证据)的影响,证据非常不确定。没有研究报告父母对新生儿重症监护病房(NICU)护理的满意度。
与非药物干预相比,关于阿片类药物对在程序中接受夹缚(MD-4.62,95%CI-6.38 至-2.86;100 名参与者,1 项研究;非常低确定性证据)或感觉刺激(MD 0.32,95%CI-1.13 至 1.77;100 名参与者,1 项研究;非常低确定性证据)时 CRIES 评分的影响,证据非常不确定。其他主要结局未报告。
与其他镇痛剂或镇静剂相比,关于阿片类药物对在程序中 PIPP/PIPP-R 评分(MD-0.29,95%CI-1.58 至 1.01;124 名参与者,2 项研究;非常低确定性证据)、程序后 30 分钟(MD-1.10,95%CI-2.82 至 0.62;12 名参与者,1 项研究;非常低确定性证据)和程序后 1 至 2 小时(MD-0.17,95%CI-2.22 至 1.88;12 名参与者,1 项研究;非常低确定性证据)的影响,证据非常不确定。没有研究报告任何危害。关于阿片类药物对在程序中(RR 3.27,95%CI 0.85 至 12.58;124 名参与者,2 项研究;非常低确定性证据)和程序后(RR 2.71,95%CI 0.11 至 64.96;124 名参与者,2 项研究;非常低确定性证据)呼吸暂停发作以及低血压(RR 1.34,95%CI 0.32 至 5.59;204 名参与者,3 项研究;非常低确定性证据)的影响,证据非常不确定。其他主要结局未报告。
我们没有发现比较不同阿片类药物(如吗啡与芬太尼)或相同阿片类药物不同给药途径(如口服吗啡与静脉内吗啡)的研究。
与安慰剂相比,阿片类药物可能会减轻程序性疼痛评分(采用 PIPP/PIPP-R 量表评估);可能会减轻 NIPS 评分;并可能导致在程序后 1 至 2 小时的 DAN 评分差异无统计学意义。关于阿片类药物对其他疼痛评分或不同时间点的影响,证据非常不确定。没有研究报告任何危害。关于阿片类药物对心动过缓和低血压发作的影响,证据非常不确定。阿片类药物可能会导致呼吸暂停发作增加。没有研究报告父母对 NICU 护理的满意度。关于阿片类药物与非药物干预或与其他镇痛剂相比,在任何结局上的影响,证据非常不确定。我们没有发现比较阿片类药物的研究,也没有比较不同阿片类药物或相同阿片类药物不同给药途径的研究。